Addex Therapeutics（APE）株式概要Addex Therapeutics社は、スイスで中枢神経系（CNS）疾患用の低分子医薬品の発見、開発、商業化を行っている。 詳細APE ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( CHF109K )キャッシュランウェイが1年未満である 意味のある時価総額がありません ( €5M )+1 さらなるリスクすべてのリスクチェックを見るAPE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW473,046 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA473,046 investors already sharing narrativesYour Fair Value€Current Price€0.03354.9k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m5m2016201920222025202620282031Revenue CHF 3.6kEarnings CHF 531.7AdvancedSet Fair ValueView all narrativesAddex Therapeutics Ltd 競合他社BiofronteraSymbol: XTRA:B8FKMarket cap: €14.6mTFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mMPH Health CareSymbol: DB:93M1Market cap: €103.2mCantourage GroupSymbol: XTRA:HIGHMarket cap: €71.3m価格と性能株価の高値、安値、推移の概要Addex Therapeutics過去の株価現在の株価CHF 0.03352週高値CHF 0.06852週安値CHF 0.031ベータ21ヶ月の変化-19.51%3ヶ月変化-34.00%1年変化0%3年間の変化n/a5年間の変化n/aIPOからの変化-99.90%最新ニュースBoard Change • Jul 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Isaac Manke was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jul 09Addex Therapeutics Publishes Preclinical Research Demonstrating Therapeutic Potential Of ADX71743 In Regulating Sleep And WakefulnessAddex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 as an important mechanism regulating key brain functions and a promising therapeutic target across a range of central nervous system disorders, including mood disorders, anxiety disorders, post-traumatic stress disorder (PTSD), and other conditions associated with dysregulated stress responses. In the study, ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats. The compound also altered stress-induced changes in key neurotransmitters, including glutamate, GABA and monoamines, across multiple brain regions in awake animals, producing neurochemical effects consistent with modulation of stress-responsive neural circuits. Together, these findings further validate the pharmacological profile of selective mGlu7 inhibition in vivo and provide additional support for the therapeutic potential of this novel mechanism. Previous studies have demonstrated that selective mGlu7 inhibition can modulate anxiety-related behaviours, disrupt maladaptive fear memory reconsolidation and influence glutamatergic signalling in both rodent and human brain tissue. ADX71743 is a potent, selective, brain-penetrant negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). The compound has served as the prototype molecule underpinning numerous publications investigating the therapeutic potential of mGlu7 modulation across anxiety, stress-related disorders, sleep regulation, fear memory and visceral pain. ADX71743 was discovered by Addex and now forms part of the mGlu7 program being advanced by Neurosterix, the neuroscience company launched by Addex and Perceptive Advisors in 2024.お知らせ • Jun 09Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026, at 11:00 W. Europe Standard Time. Location: at the campus biotech, chemin des mines 9,1202., geneva Switzerlandお知らせ • May 02Addex Therapeutics Ltd announced delayed 20-F filingOn 04/30/2026, Addex Therapeutics Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • May 01Addex Therapeutics Demonstrates Solid Anti-Tussive Activity of GABAB PAM Candidate in Bleomycin IPF-Related Chronic Cough ModelAddex Therapeutics announced encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. In studies evaluating chronic once-daily (QD) administration of a lead GABAB PAM candidate in BLM-exposed animals, robust and sustained antitussive efficacy was observed, with significant reductions in cough frequency and increased cough latency over the treatment period. Improved lung pathology outcomes, including lower Ashcroft scores and reduced percentage of affected lung tissue suggesting an impact on fibrosis, were demonstrated compared to untreated BLM-exposed animals at both Day 7 and Day 28. The safety profile remained favorable, with no meaningful changes in respiratory rate, or body temperature. The compound was well tolerated throughout the study, supporting its potential for chronic administration. The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.お知らせ • Apr 22Addex Therapeutics Ltd Demonstrates Robust Anti-Tussive Activity of Gabab Pam Candidate in Non-Human Primate Chronic Cough ModelAddex Therapeutics Ltd. announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen. As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate.最新情報をもっと見るRecent updatesBoard Change • Jul 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Isaac Manke was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jul 09Addex Therapeutics Publishes Preclinical Research Demonstrating Therapeutic Potential Of ADX71743 In Regulating Sleep And WakefulnessAddex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 as an important mechanism regulating key brain functions and a promising therapeutic target across a range of central nervous system disorders, including mood disorders, anxiety disorders, post-traumatic stress disorder (PTSD), and other conditions associated with dysregulated stress responses. In the study, ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats. The compound also altered stress-induced changes in key neurotransmitters, including glutamate, GABA and monoamines, across multiple brain regions in awake animals, producing neurochemical effects consistent with modulation of stress-responsive neural circuits. Together, these findings further validate the pharmacological profile of selective mGlu7 inhibition in vivo and provide additional support for the therapeutic potential of this novel mechanism. Previous studies have demonstrated that selective mGlu7 inhibition can modulate anxiety-related behaviours, disrupt maladaptive fear memory reconsolidation and influence glutamatergic signalling in both rodent and human brain tissue. ADX71743 is a potent, selective, brain-penetrant negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). The compound has served as the prototype molecule underpinning numerous publications investigating the therapeutic potential of mGlu7 modulation across anxiety, stress-related disorders, sleep regulation, fear memory and visceral pain. ADX71743 was discovered by Addex and now forms part of the mGlu7 program being advanced by Neurosterix, the neuroscience company launched by Addex and Perceptive Advisors in 2024.お知らせ • Jun 09Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026, at 11:00 W. Europe Standard Time. Location: at the campus biotech, chemin des mines 9,1202., geneva Switzerlandお知らせ • May 02Addex Therapeutics Ltd announced delayed 20-F filingOn 04/30/2026, Addex Therapeutics Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • May 01Addex Therapeutics Demonstrates Solid Anti-Tussive Activity of GABAB PAM Candidate in Bleomycin IPF-Related Chronic Cough ModelAddex Therapeutics announced encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. In studies evaluating chronic once-daily (QD) administration of a lead GABAB PAM candidate in BLM-exposed animals, robust and sustained antitussive efficacy was observed, with significant reductions in cough frequency and increased cough latency over the treatment period. Improved lung pathology outcomes, including lower Ashcroft scores and reduced percentage of affected lung tissue suggesting an impact on fibrosis, were demonstrated compared to untreated BLM-exposed animals at both Day 7 and Day 28. The safety profile remained favorable, with no meaningful changes in respiratory rate, or body temperature. The compound was well tolerated throughout the study, supporting its potential for chronic administration. The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.お知らせ • Apr 22Addex Therapeutics Ltd Demonstrates Robust Anti-Tussive Activity of Gabab Pam Candidate in Non-Human Primate Chronic Cough ModelAddex Therapeutics Ltd. announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen. As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate.お知らせ • Mar 09Addex Therapeutics Ltd to Report Fiscal Year 2025 Final Results on Apr 27, 2026Addex Therapeutics Ltd announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 27, 2026お知らせ • Jan 14+ 3 more updatesAddex Therapeutics Ltd to Report Q3, 2026 Results on Nov 09, 2026Addex Therapeutics Ltd announced that they will report Q3, 2026 results on Nov 09, 2026お知らせ • Jan 07Addex Spin-Out Neurosterix Starts A Phase 1 Clinical Study with M4 Pam - Ntx-253 for SchizophreniaAddex Therapeutics Ltd. announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. The progression of NTX-253 into clinical studies represents an important milestone for both Neurosterix and Addex. The M4 muscarinic receptor is a validated target for treating schizophrenia and related disorders through indirect modulation of dopamine signaling. NTX-253 is an potent, selective, orally available PAM of M4 that fine-tunes muscarinic signaling with the potential to reduce psychosis symptoms while avoiding the movement disorders and metabolic complications associated with traditional dopamine antagonists. Preclinical studies demonstrate robust antipsychotic-like activity and a favorable safety profile, supporting advancement into first-in-human clinical studies. Currently available antipsychotics typically target dopamine receptors, providing some success in ameliorating the positive symptoms of the disorder. However, targeting dopamine also can induce metabolic, cognitive, and motor side effects, limiting their therapeutic utility. Research suggest that M4 PAMs could indirectly modulate dopamine levels and induce antipsychotic activity without peripheral muscarinic side- effects seen with direct agonists. Highly selective M4 PAMs have been found to have robust antipsychotic-like effects in multiple rodent models and reverse multiple in vivo effects of psychomotorstimulants that induce increases in extracellular dopamine.お知らせ • Jun 18Addex Therapeutics Ltd to Report Q1, 2025 Results on Jun 19, 2025Addex Therapeutics Ltd announced that they will report Q1, 2025 results on Jun 19, 2025お知らせ • Jun 06Addex Therapeutics Announces Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical ModelsAddex Therapeutics announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10thAmerican Cough Conference, in Dulles, Virginia by Dr. Mikhail Kalinichev, Head of Translational Science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM Drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuPHine, baclofen), or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate. About GABAB activation and cough: The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.お知らせ • Jun 04Addex Therapeutics Ltd, Annual General Meeting, Jun 24, 2025Addex Therapeutics Ltd, Annual General Meeting, Jun 24, 2025, at 11:00 W. Europe Standard Time. Location: campus biotech, chemin des mines 9, 1202, geneva Switzerland株主還元APEDE PharmaceuticalsDE 市場7D-17.5%-3.3%0.3%1Y0%43.7%3.0%株主還元を見る業界別リターン: APE過去 1 年間で43.7 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: APEは、過去 1 年間で3 % のリターンを上げたGerman市場を下回りました。価格変動Is APE's price volatile compared to industry and market?APE volatilityAPE Average Weekly Movement19.6%Pharmaceuticals Industry Average Movement5.4%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: APEの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: APEの 週次ボラティリティ は過去 1 年間で39%から20%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20023Tim Dyerwww.addextherapeutics.comAddex Therapeutics Ltd.は、スイスで中枢神経系（CNS）疾患のための低分子医薬品の発見、開発、商業化を行なっている。同社はGタンパク質共役受容体および酵素の発見に注力している。主要開発品には、パーキンソン病レボドパ誘発性ジスキネジア・ジストニア治療薬Dipraglurant、てんかん治療薬新規経口活性型メタボトロピックグルタミン酸受容体サブタイプ2陽性アロステリックモジュレーター（mGlu2 PAM）ADX71149、疼痛・不安・過活動膀胱・中毒・物質使用障害治療薬GABAB PAMなどがある。アデクス・セラピューティクス社は、ヤンセン・ファーマシューティカルズ社と中枢神経系および関連疾患の治療を目的とした新規mGlu2 PAM化合物の探索・開発・商業化に関するライセンス契約および共同研究契約を、インディヴィオールPLC社と依存症およびその他の中枢神経系疾患の治療を目的とした新規GABAB PAM化合物の探索・開発・商業化に関するライセンス契約および研究契約を、シャルコー・マリー・トゥース協会とCMT1Aの前臨床モデルにおけるGABAB PAM化合物の役割を評価するための共同研究契約を締結している。同社は以前はAddex Pharmaceuticals Ltd.として知られていた。Addex Therapeutics Ltdは2002年に設立され、スイスのジュネーブに本社を置いている。もっと見るAddex Therapeutics Ltd 基礎のまとめAddex Therapeutics の収益と売上を時価総額と比較するとどうか。APE 基礎統計学時価総額€4.97m収益（TTM）-€7.53m売上高(TTM)€116.40k42.7xP/Sレシオ-0.7xPER（株価収益率APE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計APE 損益計算書（TTM）収益CHF 109.50k売上原価CHF 551.71k売上総利益-CHF 442.22kその他の費用CHF 6.64m収益-CHF 7.08m直近の収益報告Mar 31, 2026次回決算日Aug 24, 2026一株当たり利益（EPS）-0.059グロス・マージン-403.87%純利益率-6,467.33%有利子負債／自己資本比率0%APE の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/14 03:35終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Addex Therapeutics Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Volker BosseBaader Helvea Equity ResearchThomas MeyerBaader Helvea Equity ResearchLeonildo DelgadoBaader Helvea Equity Research6 その他のアナリストを表示
Board Change • Jul 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Isaac Manke was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jul 09Addex Therapeutics Publishes Preclinical Research Demonstrating Therapeutic Potential Of ADX71743 In Regulating Sleep And WakefulnessAddex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 as an important mechanism regulating key brain functions and a promising therapeutic target across a range of central nervous system disorders, including mood disorders, anxiety disorders, post-traumatic stress disorder (PTSD), and other conditions associated with dysregulated stress responses. In the study, ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats. The compound also altered stress-induced changes in key neurotransmitters, including glutamate, GABA and monoamines, across multiple brain regions in awake animals, producing neurochemical effects consistent with modulation of stress-responsive neural circuits. Together, these findings further validate the pharmacological profile of selective mGlu7 inhibition in vivo and provide additional support for the therapeutic potential of this novel mechanism. Previous studies have demonstrated that selective mGlu7 inhibition can modulate anxiety-related behaviours, disrupt maladaptive fear memory reconsolidation and influence glutamatergic signalling in both rodent and human brain tissue. ADX71743 is a potent, selective, brain-penetrant negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). The compound has served as the prototype molecule underpinning numerous publications investigating the therapeutic potential of mGlu7 modulation across anxiety, stress-related disorders, sleep regulation, fear memory and visceral pain. ADX71743 was discovered by Addex and now forms part of the mGlu7 program being advanced by Neurosterix, the neuroscience company launched by Addex and Perceptive Advisors in 2024.
お知らせ • Jun 09Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026, at 11:00 W. Europe Standard Time. Location: at the campus biotech, chemin des mines 9,1202., geneva Switzerland
お知らせ • May 02Addex Therapeutics Ltd announced delayed 20-F filingOn 04/30/2026, Addex Therapeutics Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • May 01Addex Therapeutics Demonstrates Solid Anti-Tussive Activity of GABAB PAM Candidate in Bleomycin IPF-Related Chronic Cough ModelAddex Therapeutics announced encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. In studies evaluating chronic once-daily (QD) administration of a lead GABAB PAM candidate in BLM-exposed animals, robust and sustained antitussive efficacy was observed, with significant reductions in cough frequency and increased cough latency over the treatment period. Improved lung pathology outcomes, including lower Ashcroft scores and reduced percentage of affected lung tissue suggesting an impact on fibrosis, were demonstrated compared to untreated BLM-exposed animals at both Day 7 and Day 28. The safety profile remained favorable, with no meaningful changes in respiratory rate, or body temperature. The compound was well tolerated throughout the study, supporting its potential for chronic administration. The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.
お知らせ • Apr 22Addex Therapeutics Ltd Demonstrates Robust Anti-Tussive Activity of Gabab Pam Candidate in Non-Human Primate Chronic Cough ModelAddex Therapeutics Ltd. announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen. As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate.
Board Change • Jul 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Independent Director Isaac Manke was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jul 09Addex Therapeutics Publishes Preclinical Research Demonstrating Therapeutic Potential Of ADX71743 In Regulating Sleep And WakefulnessAddex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 as an important mechanism regulating key brain functions and a promising therapeutic target across a range of central nervous system disorders, including mood disorders, anxiety disorders, post-traumatic stress disorder (PTSD), and other conditions associated with dysregulated stress responses. In the study, ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats. The compound also altered stress-induced changes in key neurotransmitters, including glutamate, GABA and monoamines, across multiple brain regions in awake animals, producing neurochemical effects consistent with modulation of stress-responsive neural circuits. Together, these findings further validate the pharmacological profile of selective mGlu7 inhibition in vivo and provide additional support for the therapeutic potential of this novel mechanism. Previous studies have demonstrated that selective mGlu7 inhibition can modulate anxiety-related behaviours, disrupt maladaptive fear memory reconsolidation and influence glutamatergic signalling in both rodent and human brain tissue. ADX71743 is a potent, selective, brain-penetrant negative allosteric modulator of metabotropic glutamate receptor 7 (mGlu7). The compound has served as the prototype molecule underpinning numerous publications investigating the therapeutic potential of mGlu7 modulation across anxiety, stress-related disorders, sleep regulation, fear memory and visceral pain. ADX71743 was discovered by Addex and now forms part of the mGlu7 program being advanced by Neurosterix, the neuroscience company launched by Addex and Perceptive Advisors in 2024.
お知らせ • Jun 09Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026, at 11:00 W. Europe Standard Time. Location: at the campus biotech, chemin des mines 9,1202., geneva Switzerland
お知らせ • May 02Addex Therapeutics Ltd announced delayed 20-F filingOn 04/30/2026, Addex Therapeutics Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • May 01Addex Therapeutics Demonstrates Solid Anti-Tussive Activity of GABAB PAM Candidate in Bleomycin IPF-Related Chronic Cough ModelAddex Therapeutics announced encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. In studies evaluating chronic once-daily (QD) administration of a lead GABAB PAM candidate in BLM-exposed animals, robust and sustained antitussive efficacy was observed, with significant reductions in cough frequency and increased cough latency over the treatment period. Improved lung pathology outcomes, including lower Ashcroft scores and reduced percentage of affected lung tissue suggesting an impact on fibrosis, were demonstrated compared to untreated BLM-exposed animals at both Day 7 and Day 28. The safety profile remained favorable, with no meaningful changes in respiratory rate, or body temperature. The compound was well tolerated throughout the study, supporting its potential for chronic administration. The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.
お知らせ • Apr 22Addex Therapeutics Ltd Demonstrates Robust Anti-Tussive Activity of Gabab Pam Candidate in Non-Human Primate Chronic Cough ModelAddex Therapeutics Ltd. announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen. As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate.
お知らせ • Mar 09Addex Therapeutics Ltd to Report Fiscal Year 2025 Final Results on Apr 27, 2026Addex Therapeutics Ltd announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 27, 2026
お知らせ • Jan 14+ 3 more updatesAddex Therapeutics Ltd to Report Q3, 2026 Results on Nov 09, 2026Addex Therapeutics Ltd announced that they will report Q3, 2026 results on Nov 09, 2026
お知らせ • Jan 07Addex Spin-Out Neurosterix Starts A Phase 1 Clinical Study with M4 Pam - Ntx-253 for SchizophreniaAddex Therapeutics Ltd. announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. The progression of NTX-253 into clinical studies represents an important milestone for both Neurosterix and Addex. The M4 muscarinic receptor is a validated target for treating schizophrenia and related disorders through indirect modulation of dopamine signaling. NTX-253 is an potent, selective, orally available PAM of M4 that fine-tunes muscarinic signaling with the potential to reduce psychosis symptoms while avoiding the movement disorders and metabolic complications associated with traditional dopamine antagonists. Preclinical studies demonstrate robust antipsychotic-like activity and a favorable safety profile, supporting advancement into first-in-human clinical studies. Currently available antipsychotics typically target dopamine receptors, providing some success in ameliorating the positive symptoms of the disorder. However, targeting dopamine also can induce metabolic, cognitive, and motor side effects, limiting their therapeutic utility. Research suggest that M4 PAMs could indirectly modulate dopamine levels and induce antipsychotic activity without peripheral muscarinic side- effects seen with direct agonists. Highly selective M4 PAMs have been found to have robust antipsychotic-like effects in multiple rodent models and reverse multiple in vivo effects of psychomotorstimulants that induce increases in extracellular dopamine.
お知らせ • Jun 18Addex Therapeutics Ltd to Report Q1, 2025 Results on Jun 19, 2025Addex Therapeutics Ltd announced that they will report Q1, 2025 results on Jun 19, 2025
お知らせ • Jun 06Addex Therapeutics Announces Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical ModelsAddex Therapeutics announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10thAmerican Cough Conference, in Dulles, Virginia by Dr. Mikhail Kalinichev, Head of Translational Science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM Drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuPHine, baclofen), or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate. About GABAB activation and cough: The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound.
お知らせ • Jun 04Addex Therapeutics Ltd, Annual General Meeting, Jun 24, 2025Addex Therapeutics Ltd, Annual General Meeting, Jun 24, 2025, at 11:00 W. Europe Standard Time. Location: campus biotech, chemin des mines 9, 1202, geneva Switzerland
